Navigation Links
J591- an Antibody Exclusively Targets Tumors

A clinical trial confirms that an antibody called J591 specifically targets an antigen found in high amounts in prostate tumors// and on blood vessels of all solid tumors.

Researchers at NewYork-Presbyterian Hospital and Weill Cornell Medical Center conducted this study.

Since the prostate-specific membrane antigen (PSMA) exists only on tumors and not other tissues, J591 armed with a drug or radiation offers a way to selectively target cancer while leaving healthy tissues unharmed, thereby resulting in very low levels of toxicity and fewer side effects for patients.

While the study, published in the Feb. 10 issue of the Journal of Clinical Oncology, was designed to prove that J591 could exclusively target tumors (it did not try to reduce tumor size), researchers now have a vehicle for selectively transporting drugs or a radioactive isotope to destroy the blood vessels that feed tumors, thereby cutting off the cancer's blood supply.

"This was a proof-of-principle study designed purely to confirm that we could successfully target tumor vasculature without targeting normal tissue," said the study's senior author, Dr. Neil H. Bander, a urological cancer specialist at the medical center and the Bernard and Josephine Chaus Professor of Urological Oncology at Weill Cornell Medical College.

"Now that we have confirmed specific and accurate targeting, in subsequent studies we will arm the J591 antibody with drugs or radioactivity, and then we will assess tumor response. We are already using such armed antibodies in patients with prostate cancer and have been able to show significant anti-tumor activity."

The research team used a radioactive tracer, attached to the antibody, to follow J591's progress throughout the body. The trial involved 27 cancer patients with a wide range of solid tumors -- including kidney, bladder, lung, breast, colorectal, pancreas and melanoma. All patients had widespread disease
'"/>




Page: 1 2

Related medicine news :

1. Human Antibody That Can Block SARS
2. Therapeutic Monoclonal Antibody Production Is More Profitable Than Small Molecule Drugs
3. Cuba Registers New Antibody
4. Single Sugar Enables Antibody to Treat Inflammation
5. Monoclonal Antibody based system for Anthrax detection
6. Monoclonal Antibody Reduces Exacerbations in Asthmatics
7. Anti-rejection Therapy a Boon for Patients With "anti-donor" Antibody Levels
8. Antibody Therapy Prevents Type 1 Diabetes
9. New Antibody for EGFR Causes Lung Cancer Regression
10. Research Targets treatment for dementia and brain injuries
11. Cancer Treatments Fall Short Of Targets
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Antibody Exclusively Targets Tumors

(Date:11/24/2014)... (PRWEB) November 24, 2014 Olaparib functions ... polymerase (PARP) and is one of the first PARP ... to creating some types of melanoma, and are often ... also sometimes gives their malignancies a exclusive weaknesses, as ... to fix their DNA and allow them to proceed ...
(Date:11/24/2014)... The Holiday Inn Westbury - Long ... Children's Association to donate various items consisting of ... other such items.The Association's program is aimed toward helping ... in nursing homes, assisted living facilities and nursing homes. ... being of seniors throughout the Long Island area. The ...
(Date:11/24/2014)... Raymond, Alberta (PRWEB) November 24, 2014 ... of people each day. They break up families, ... there is new hope for those that suffer,” ... “Ground-breaking scientific research is showing that our specialized ... , Hardy will appear on “Mind Over Matter”, ...
(Date:11/24/2014)... SafeHandles™ announced that they will be featured in ... airing via Discovery Channel. Dates and show times TBA. ... replaceable, and affordable germ protective device. This segment will ... adhesives to promote hand hygiene in high traffic and ... is the desire to make a positive impact in ...
(Date:11/24/2014)... Gersowitz Libo & Korek, P.C., a leading ... Tier recognition in the 2015 Edition of U.S. News-Best Lawyers ... a unique combination of quality law practice and breadth of ... honor and especially grateful to our clients whose continued support ... possible,” said Jeff S. Korek, senior partner at Gersowitz ...
Breaking Medicine News(10 mins):Health News:Olaparib Industry (CAS 763113-22-0) 2009-2019 Global and China Research Reports is Now Available at RnRMarketResearch.com 2Health News:Olaparib Industry (CAS 763113-22-0) 2009-2019 Global and China Research Reports is Now Available at RnRMarketResearch.com 3Health News:Olaparib Industry (CAS 763113-22-0) 2009-2019 Global and China Research Reports is Now Available at RnRMarketResearch.com 4Health News:The Holiday Inn Westbury - Long Island gives back to the local Long Island community, and also goes beyond borders to assist those in need during the 2014 Holiday Season 2Health News:The Holiday Inn Westbury - Long Island gives back to the local Long Island community, and also goes beyond borders to assist those in need during the 2014 Holiday Season 3Health News:Nutritional Mental Health Treatment Featured on Access Health Airing on Lifetime Television® 2Health News:Nutritional Mental Health Treatment Featured on Access Health Airing on Lifetime Television® 3Health News:New Episode of Innovations TV Series to Feature SafeHandles™ 2Health News:U.S. News-Best Lawyers “Best Law Firms” Names Gersowitz Libo & Korek P.C. a 2015 Tier 1 Ranking Firm 2
... Sept. 21 Roper Industries,Inc. (NYSE: ROP ) ... 2007, ended September 30, 2007, will be released after ... call to discuss these results,has been scheduled for 10:00 ... be accessed via webcast or by dialing +1 888-801-6506 ...
... SAN DIEGO, Sept. 21 ChemDiv, Inc. (San ... (CDRI, Moscow) is,undertaking a partnership with the Blokhin ... Medical Sciences, the US Department of Energy,(DOE), and ... novel small,molecule therapies for the prevention and treatment ...
... On Sept. 18, the,Michigan Association of Health Plans ... award reception at which eight Michigan HMOs received,the ... as these,are leading the way in serving participants ... "Michigan needs more,health care plans that expand outreach, ...
... are at high risk for preterm birth, giving them a ... babys chances of having serious lung problems after birth. , ... new study shows that repeat courses of corticosteroids are linked ... these mothers. , Our study shows that you get almost ...
... of studies shows big survival gains , THURSDAY, ... regimens of irinotecan, oxaliplatin, and molecular-targeted treatments are ... months longer than they did a few years ... say. , Researchers at the University of Ioannina ...
... 18, 2007 -- Recently, researchers at Iowa State University ... popular crop model. By zeroing in on early stages ... help improve yield predictions across a variety of environmental ... the September-October issue of Crop Science. , The Crop ...
Cached Medicine News:Health News:Chemical Diversity Initiates International Prostrate Cancer Discovery Partnership 2Health News:Chemical Diversity Initiates International Prostrate Cancer Discovery Partnership 3Health News:Eight Michigan HMOs, Two Providers, Take Top Honors for Quality Health Care 2Health News:Eight Michigan HMOs, Two Providers, Take Top Honors for Quality Health Care 3Health News:Multiple corticosteroid injections in pregnant women may increase cerebral palsy 2Health News:Experts Compare Colon Cancer Treatment Outcomes 2Health News:Simulating kernel production influences maize model accuracy 2
(Date:11/24/2014)... DIEGO , Nov. 24, 2014  GlySens Incorporated ... two million dollar grant from the National Institute of ... of the National Institutes of Health (NIH).  The grant ... GlySens second generation ICGM™ long term implantable glucose monitoring ... underway, and enrollment is expected to begin before the ...
(Date:11/23/2014)... HAYWARD, Calif. , Nov. 23, 2014 ... today that Paul F. Truex , President and ... the 2014 Annual Piper Jaffray Healthcare Conference. ... rd , at the Palace Hotel in ... Anthera Pharmaceuticals Anthera Pharmaceuticals is a biopharmaceutical ...
(Date:11/22/2014)... de 2014  BioClinica®, Inc., un proveedor líder ... eClinical, ha indicado un aumento de la demanda ... seguimiento basado en el riesgo en los ensayos ... seguimiento basado en el riesgo más allá de ... o cambio de los métodos de seguimiento. Se ...
Breaking Medicine Technology:GlySens Incorporated Awarded $2 Million Grant from the National Institutes of Health 2Anthera Pharmaceuticals to Present at Annual Piper Jaffray Healthcare Conference 2El 'seguimiento inteligente' consigue un excelente momento 2El 'seguimiento inteligente' consigue un excelente momento 3
... PLC ), a company focused on innovative cardiac ... the three,and twelve month periods ended December 31, 2007., ... with,$1,747,000 in the fourth quarter of 2006. The net ... $0.03 per diluted share, compared to net,income of $36,000, ...
... XYOTAX to be reviewed for PS2 first-line non-small cell lung cancer ... ... March 4 Cell Therapeutics, Inc.,(CTI) (Nasdaq and MTA: CTIC) announced ... Medicines Agency (EMEA) for,XYOTAX(TM) (paclitaxel poliglumex, CT-2103) for first-line treatment of,patients ...
Cached Medicine Technology:PLC Systems Reports Fourth Quarter 2007 Results 2PLC Systems Reports Fourth Quarter 2007 Results 3PLC Systems Reports Fourth Quarter 2007 Results 4PLC Systems Reports Fourth Quarter 2007 Results 5PLC Systems Reports Fourth Quarter 2007 Results 6Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM) 2Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM) 3Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM) 4
Khosla Precision and Quality in Medical and Surgical Products....
Khosla Precision and Quality in Medical and Surgical Products....
Khosla Precision and Quality in Medical and Surgical Products....
... For Anterior and Posterior segment surgeries ... using Ventury or Peristaltic Linear Aspiration. ... for specific cutting action. Easy to ... movement. Cutting speed-variable from 1- 600 ...
Medicine Products: